All

Enterome initiates first clinical trial with EO2401 – an innovative microbiomeantigen based cancer immunotherapy candidate targeting aggressive brain cancer
30 July 2020

Enterome initiates first clinical trial with EO2401 – an innovative microbiomeantigen based cancer immunotherapy candidate targeting aggressive brain cancer

ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunoinflammation axis to develop next-generation therapeutics,...

Read the press release
Clim8 raises €2.75m Series A funding
27 July 2020

Clim8 raises €2.75m Series A funding

The French company, founded in 2016, is a leader in the connected textiles market with its intelligent and patented thermal technologies. With more than 50% of its sales...

Read the press release
Tubulis Raises €10.7 M Series A to Advance Development of a New Generation of Antibody-Drug Conjugates
21 July 2020

Tubulis Raises €10.7 M Series A to Advance Development of a New Generation of Antibody-Drug Conjugates

Tubulis announced the close of a €10.7 million Series A financing round to accelerate the development of a new class of highly stable and efficient antibody-drug conjugates...

Read the press release
Citryll completes € 18.5 M fundraise to develop CIT-013, an antibody targeting Neutrophil Extracellular Traps
2 July 2020

Citryll completes € 18.5 M fundraise to develop CIT-013, an antibody targeting Neutrophil Extracellular Traps

OSS, Netherlands-Citryll announced it closed a total fundraise of € 18.5 million, led by Seventure (including their Health for Life Capital II fund), co-led by BioGeneration...

Read more
Transfergo raises $10M additional funding, launches in 11 new markets
16 June 2020

Transfergo raises $10M additional funding, launches in 11 new markets

TransferGo, the London-based international money transfer service, has raised another $10 million in funding, as it discloses that its customer numbers have surpassed two...

Read more
CARB-X FUNDS ELIGO BIOSCIENCE TO DEVELOP CRISPR-BASED THERAPEUTICS DERIVED FROM BACTERIOPHAGES TO KILL SUPERBUGS AND PREVENT DEADLY INFECTIONS IN TRANSPLANT PATIENTS
2 July 2020

CARB-X FUNDS ELIGO BIOSCIENCE TO DEVELOP CRISPR-BASED THERAPEUTICS DERIVED FROM BACTERIOPHAGES TO KILL SUPERBUGS AND PREVENT DEADLY INFECTIONS IN TRANSPLANT PATIENTS

(BOSTON) – CARB-X announced today that it is awarding up to US$1.82 million to Eligo Bioscience in Paris, France, with additional funding for a total award of up to US$7.05...

Read more
Enterome completes €46.3 million ($52.6 million) financing to progress the clinical development of its therapeutic pipeline
25 June 2020

Enterome completes €46.3 million ($52.6 million) financing to progress the clinical development of its therapeutic pipeline

ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunoinflammation axis to develop next-generation therapeutics, today...

Read the press release
Lecturio is Providing Free Learning Resources to Help Combat the COVID-19 Pandemic
19 June 2020

Lecturio is Providing Free Learning Resources to Help Combat the COVID-19 Pandemic

Due to the growing COVID-19 pandemic, the need for qualified healthcare professionals is growing worldwide. The video learning provider Lecturio has created a COVID-19...

Read more
MedinCell announces the great success of its capital increase and raises 15.6 M€
17 June 2020

MedinCell announces the great success of its capital increase and raises 15.6 M€

MedinCell (FR0004065605 - MEDCL), a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas (the...

Read more